Treatment of Psoriatic Arthritis with Tumor Necrosis Factor Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL)
- 1 July 2012
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 89, 90-93
- https://doi.org/10.3899/jrheum.120254
Abstract
Objective. To assess longer-term outcomes, including enthesitis and dactylitis, in patients with active psoriatic arthritis (PsA), in a study of golimumab treatment. Methods. Adult patients with active PsA were randomized to receive subcutaneous injections of placebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146) every 4 weeks through Week 20. All patients received golimumab 50 mg or 100 mg from Week 24 onward. Entheses tenderness was scored in 15 body sites using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score (MASES). Dactylitis was assessed in 20 digits of the hands and feet. Results. Among the 405 randomized patients, 77% presented with enthesitis and 34% dactylitis at baseline. At Week 24 of the placebo-controlled study phase, significant differences were observed between golimumab 50 mg and/or 100 mg and placebo for mean percent improvement in the PsA-modified MASES [46% (p < 0.001) and 52% (p < 0.001) vs 13%, respectively] and the dactylitis score [66% (p = 0.09) and 82% (p < 0.001) vs 28%, respectively]. By Week 52, improvements were maintained among patients randomized to receive golimumab (mean improvements of 54% for PsA-modified MASES and 77% for the dactylitis score). Those given placebo who had enthesitis or dactylitis at baseline and who crossed over to golimumab at Week 16 or 24 had somewhat less improvement at Week 52 (i.e., 39% for the PsA-modified MASES, 57% for dactylitis score). Conclusion. Treatment of PsA patients with the TNF inhibitor golimumab was effective across all components of disease, including enthesitis and dactylitis, and efficacy was maintained over longer-term followup.This publication has 11 references indexed in Scilit:
- European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapiesAnnals Of The Rheumatic Diseases, 2011
- Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008The Journal of Rheumatology, 2010
- A sonographic spectrum of psoriatic arthritis: “the five targets”Clinical Rheumatology, 2009
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled studyArthritis & Rheumatism, 2009
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals Of The Rheumatic Diseases, 2009
- Treatment recommendations for psoriatic arthritisAnnals Of The Rheumatic Diseases, 2008
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rateAnnals Of The Rheumatic Diseases, 2008
- Assessment of enthesitis in ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2003
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995